NAYA Biosciences Inc (NAYA): Net earnings per share growth forecast for next year
NAYA Biosciences is optimizing expenses by outsourcing production and testing to third-party contractors. The projected earnings per share for the coming year confirms this strategy, where 11.80 serves as the base value of the parameter. Currently, NAYA Biosciences is only building its oncology customer base while awaiting licenses. Meanwhile, therapy development remains independent of GDP, ensuring high macroeconomic resilience for the business.
Analytical breakdowns and data insights for company NAYA Bio (NAYA)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
Total Debt to Capital NAYA Biosciences|NAYA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio NAYA Bio|NAYA - Aggregate Debt Obligations|Debts to Book Capitalization NAYA Biosciences Inc|NAYA - Company Long-Term Debt|Company Short-Term Debts NAYA Biosciences|Quick Liquidity nayabiosciences.com
- earnings and valuation multiples information:
NAYA - Company Net Income|Expected Profit NAYA Biosciences|NAYA - Business Payback Period|Forward P/E Multiple NAYA Biosciences Inc|NAYA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple NAYA Biosciences Corp|NAYA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) NAYA Biosciences|NAYA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months nayabiosciences.com|NAYA - Earnings per share growth this year|Earnings growth forecast for next year NAYA Biosciences
- revenue and sales proceeds data:
Fundamental company valuation:NAYA Biosciences, NAYA
The lack of in-house production facilities and a reliance on outsourcing make the financial results of NAYA Biosciences dependent on the efficiency of external contractors. This metric measures the expected percentage change in earnings per share by aggregating analyst forecasts for future profitability, which allows for a real-time assessment of the asset's current market value via this EPS n+1 consensus forecast chart.
Key competitors
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Earnings growth forecast for next year Ascentage Pharma Group International (AAPG)|Earnings growth forecast for next year CGON (CG Oncology Inc)|Expected earnings per share trend next year URGN|bicara.com - Earnings growth forecast for next year|Expected earnings per share trend next year PSNL (personalis.com)|Erasca Inc (ERAS) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Delcath Systems|YMAB (YmAbs) - Earnings growth forecast for next year|AURA: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Candel Therapeutics, Inc. (CADL)|Earnings growth forecast for next year Accuray (ARAY)|Net earnings per share growth forecast for next year SELLAS Life Sciences Group Inc. SLS|Actuate Therapeutics, Inc (ACTU) - Expected net earnings per share growth next year|CTOR - Net earnings per share growth forecast for next year|HURA: Net earnings per share growth forecast for next year|TARA (Protara) - Expected earnings per share growth for next year|Fate Therapeutics, Inc. - Expected earnings per share trend next year|WHWK (aadibio.com) - Earnings growth forecast for next year|TCRX: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Champions Oncology (CSBR)|XBiotech - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year CEL-SCI CVM|Consensus forecast of earnings per share growth for next year OS Therapies (OSTX)|Radiopharm Theranostics Limited - Earnings growth forecast for next year|Expected net earnings per share growth next year Artiva Biotherapeutics|ANL (adlainortye.com) - Expected earnings per share growth for next year|Expected earnings per share growth for next year Veru Pharma|TPST (Tempest Therapeutics Inc) - Earnings growth forecast for next year|Xilio Therapeutics, Inc. (XLO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Enochian BioSciences (RENB)|MURA: Net earnings per share change forecast for next year|Earnings growth forecast for next year KAPA (kairospharma.com)|Consensus forecast of earnings per share growth for next year OnKure (OKUR)|CytoMed Therapeutics Ltd - Earnings growth forecast for next year|curis.com (CRIS) - Expected earnings per share growth for next year|Apollomics Corp (APLM) - Net earnings per share growth forecast for next year|Tharimmune - Expected earnings per share trend next year|ADVB (Advanced Biomed Corp) - Earnings growth forecast for next year|Expected earnings per share growth for next year Genprex, Inc (GNPX)|Earnings growth forecast for next year CLDI|SBFM: Net earnings per share change forecast for next year|Earnings growth forecast for next year XBIO (xeneticbio.com)|Earnings growth forecast for next year Salarius Pharmaceuticals Inc SLRX|purple-biotech.com - Earnings growth forecast for next year|Expected net earnings per share growth next year American Oncology Network, Inc.|BGNE: Earnings growth forecast for next year|Expected earnings per share growth for next year checkpointtx.com|Net earnings per share growth forecast for next year Elevation Oncology, Inc.|iCAD, Inc. (ICAD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Ikena (IKNA)|NTBL - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year viracta.com VIRX|morphosys.com (MOR) - Expected net earnings per share growth next year|AAPGV: Expected earnings per share growth for next year
